AIMS/HYPOTHESIS: Glucagon reduces body weight by modifying food intake, glucose/lipid metabolism and energy expenditure. All these physiological processes are also controlled by fibroblast growth factor 21 (FGF-21), a circulating hepatokine that improves the metabolic profile in obesity and type 2 diabetes. Animal experiments have suggested a possible interaction between glucagon and FGF-21 however, the metabolic consequences of this crosstalk are not understood. METHODS: The effects of exogenous glucagon on plasma FGF-21 levels and lipolysis were evaluated in healthy volunteers and humans with type 1 diabetes, as well as in rodents with streptozotocin (STZ)-induced insulinopenic diabetes. In vitro, the role of glucagon on FGF-21 secretion and lipolysis was studied using isolated primary rat hepatocytes and adipocytes. Fgf-21 expression in differentiated rat pre-adipocytes was suppressed by small interfering RNA and released FGF-21 was immunoneutralised by polyclonal antibodies. RESULTS: Glucagon induced lipolysis in healthy human volunteers, patients with type 1 diabetes, mice and rats with STZ-induced insulinopenic diabetes, and in adipocytes isolated from diabetic and non-diabetic animals. In addition, glucagon increased circulating FGF-21 in healthy humans and rodents, as well as in patients with type 1 diabetes, and insulinopenic rodents. Glucagon stimulated FGF-21 secretion from isolated primary hepatocytes and adipocytes derived from animals with insulinopenic diabetes. Furthermore, FGF-21 stimulated lipolysis in primary adipocytes isolated from non-diabetic and diabetic rats. Reduction of Fgf-21 expression (by approximately 66%) or immunoneutralisation of released FGF-21 markedly attenuated glucagon-stimulated lipolysis in adipocytes. CONCLUSIONS/ INTERPRETATION: These results indicate that glucagon increases circulating FGF-21 independently of endogenous insulin levels. FGF-21 participates in glucagon-induced stimulation of lipolysis.
AIMS/HYPOTHESIS: Glucagon reduces body weight by modifying food intake, glucose/lipid metabolism and energy expenditure. All these physiological processes are also controlled by fibroblast growth factor 21 (FGF-21), a circulating hepatokine that improves the metabolic profile in obesity and type 2 diabetes. Animal experiments have suggested a possible interaction between glucagon and FGF-21 however, the metabolic consequences of this crosstalk are not understood. METHODS: The effects of exogenous glucagon on plasma FGF-21 levels and lipolysis were evaluated in healthy volunteers and humans with type 1 diabetes, as well as in rodents with streptozotocin (STZ)-induced insulinopenic diabetes. In vitro, the role of glucagon on FGF-21 secretion and lipolysis was studied using isolated primary rat hepatocytes and adipocytes. Fgf-21 expression in differentiated rat pre-adipocytes was suppressed by small interfering RNA and released FGF-21 was immunoneutralised by polyclonal antibodies. RESULTS:Glucagon induced lipolysis in healthy human volunteers, patients with type 1 diabetes, mice and rats with STZ-induced insulinopenic diabetes, and in adipocytes isolated from diabetic and non-diabetic animals. In addition, glucagon increased circulating FGF-21 in healthy humans and rodents, as well as in patients with type 1 diabetes, and insulinopenic rodents. Glucagon stimulated FGF-21 secretion from isolated primary hepatocytes and adipocytes derived from animals with insulinopenic diabetes. Furthermore, FGF-21 stimulated lipolysis in primary adipocytes isolated from non-diabetic and diabeticrats. Reduction of Fgf-21 expression (by approximately 66%) or immunoneutralisation of released FGF-21 markedly attenuated glucagon-stimulated lipolysis in adipocytes. CONCLUSIONS/ INTERPRETATION: These results indicate that glucagon increases circulating FGF-21 independently of endogenous insulin levels. FGF-21 participates in glucagon-induced stimulation of lipolysis.
Authors: Knut Mai; Thomas Bobbert; Christian Groth; Anke Assmann; Sabine Meinus; Jessica Kraatz; Janin Andres; Ayman M Arafat; Andreas F H Pfeiffer; Matthias Möhlig; Joachim Spranger Journal: Am J Physiol Endocrinol Metab Date: 2010-04-27 Impact factor: 4.310
Authors: Michael K Badman; Pavlos Pissios; Adam R Kennedy; George Koukos; Jeffrey S Flier; Eleftheria Maratos-Flier Journal: Cell Metab Date: 2007-06 Impact factor: 27.287
Authors: Peter Arner; Amanda Pettersson; Pamela J Mitchell; James D Dunbar; Alexei Kharitonenkov; Mikael Rydén Journal: FEBS Lett Date: 2008-05-05 Impact factor: 4.124
Authors: Xinmei Zhang; Dennis C Y Yeung; Michal Karpisek; David Stejskal; Zhi-Guang Zhou; Feng Liu; Rachel L C Wong; Wing-Sun Chow; Annette W K Tso; Karen S L Lam; Aimin Xu Journal: Diabetes Date: 2008-02-05 Impact factor: 9.461
Authors: Ayman M Arafat; Przemysław Kaczmarek; Marek Skrzypski; Ewa Pruszyńska-Oszmałek; Paweł Kołodziejski; Aikaterini Adamidou; Stephan Ruhla; Dawid Szczepankiewicz; Maciej Sassek; Maria Billert; Bertram Wiedenmann; Andreas F H Pfeiffer; Krzysztof W Nowak; Mathias Z Strowski Journal: Diabetologia Date: 2014-07-27 Impact factor: 10.122
Authors: Jaclyn E Welles; Michael D Dennis; Leonard S Jefferson; Scot R Kimball Journal: Am J Physiol Endocrinol Metab Date: 2020-05-18 Impact factor: 4.310
Authors: Lydia-Ann L S Harris; Gordon I Smith; Bruce W Patterson; Raja S Ramaswamy; Adewole L Okunade; Shannon C Kelly; Lane C Porter; Samuel Klein; Jun Yoshino; Bettina Mittendorfer Journal: Diabetes Date: 2017-05-04 Impact factor: 9.461
Authors: Luciano S Caixeta; Sarah L Giesy; Christopher S Krumm; James W Perfield; Anthony Butterfield; Katie M Schoenberg; Donald C Beitz; Yves R Boisclair Journal: Am J Physiol Regul Integr Comp Physiol Date: 2017-08-09 Impact factor: 3.619